Better method for detection of CD30: Immunohistochemistry or flow cytometry?

Content Provider	Europe PMC
Author	Higashi, Morihiro Kikuchi, Jun Murakami, Chiaki Takayanagi, Natsuko Momose, Shuji Kizaki, Masahiro Tamaru, Jun-ichi
Copyright Year	2021
Abstract	We compared the two methods of assessing CD30 protein expression in DLBCL and TCL specimens routinely employed at our hospital, immunohistochemistry (IHC) and flow cytometry (FCM), using the same clone of the anti-CD30 antibody (Ber-H2) in 123 patients with DLBCL and 28 patients with TCL. FCM was more sensitive than IHC, especially in cases with low expression. In three cases of TCL and two cases of DLBCL, there was discordance between these two methods. Two of these TCL cases were ALCL and one was peripheral T-cell lymphoma, NOS, but ALCL was unable to be excluded. One of two cases of DLBCL was an anaplastic variant of DLBCL. The data suggested that CD30 was undetectable, though rare, by FMC in several cases. Based on this study, a combination of IHC and FCM is recommended for the reliable and quantitative detection of CD30.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8808110&blobtype=pdf
ISSN	13464280
Journal	Journal of Clinical and Experimental Hematopathology : JCEH [J Clin Exp Hematop]
Volume Number	61
DOI	10.3960/jslrt.21019
PubMed Central reference number	PMC8808110
Issue Number	4
PubMed reference number	34511584
e-ISSN	18809952
Language	English
Publisher	JSLRT
Publisher Date	2021-09-10
Access Restriction	Open
Rights License	This is an open-access article distributed under the terms of theCreative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License. © 2021 by The Japanese Society for Lymphoreticular Tissue Research
Subject Keyword	CD30 flow cytometry immunohistochemistry diffuse large B-cell lymphoma T-cell lymphoma
Content Type	Text
Resource Type	Article
Subject	Medicine Hematology